scholarly journals Transcatheter device closure of patent ductus arteriosus without arterial access – Single institution experience

2013 ◽  
Vol 65 (5) ◽  
pp. 546-551 ◽  
Author(s):  
Gaurav Garg ◽  
Anurakti Srivastava ◽  
Himanshu Tyagi ◽  
Sridhar P. Reddy ◽  
Anil Sivadasan Radha
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Device Closure ◽  
Single Institution ◽  
Arterial Access ◽  
Transcatheter Device ◽  
Patent Ductus

Transcatheter device closure of patent ductus arteriosus by exclusive venous access under echocardiographic guidance without angiography

2021 ◽  
pp. 1-5
Author(s):  
Salem Deraz ◽  
Mohamed Tawfik ◽  
Susy Kotit ◽  
Abdelrahman Elafifi
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Vascular Complications ◽  
Venous Access ◽  
Device Closure ◽  
Arterial Access ◽  
Surgical Closure ◽  
Group 2 ◽  
Patent Ductus ◽  
Group 1

Abstract Introduction: The standard transcatheter technique to profile the patent ductus arteriosus requires arterial access through the femoral artery and is associated with arterial complications, longer fluoroscopic time, contrast volume, and longer hospital stay. Aim of the study: To compare exclusive transvenous access with the standard procedures for patent ductus arteriosus closure and evaluate whether exclusive venous approach is a safe and effective alternative. Methods: A total of 320 patients were included. A detailed echocardiographic evaluation of the duct morphology was performed. Patients were classified into group 1 included patients who underwent exclusive femoral venous access, without any injections of contrast media and group 2 included patients who underwent arterial and venous access. Results: Arterial access was achieved in 210 (65.6%). Successful closure of patent ductus arteriosus was achieved in 109 (99.1%) patients in group 1 and in 203 (96.7%) patients in group 2. The patent ductus arteriosus was large and was referred for surgical closure in one patient from group 1 and 7 patients from group 2. Residual patent ductus arteriosus was seen in 6 cases from group 1 (5.4%) and 12 patients from group 2 (5.7%). None of the cases in group 1 had vascular complications, while vascular complications were seen in 20 cases, all of them in group 2 (9.5%). Nonvascular complications were seen in one patient from group 1 (0.9%) and 15 patients in group 2 (7.1%). The procedure time and fluoroscopy times were less in patients with exclusive transvenous access. Conclusion: Patent ductus arteriosus device closure without arterial access can be accomplished safely and effectively.

Intracardiac echocardiography: use during transcatheter device closure of a patent ductus arteriosus in a dog

2017 ◽  
Vol 19 (3) ◽  
pp. 293-298 ◽  
Author(s):  
V. Chetboul ◽  
C. Damoiseaux ◽  
L. Behr ◽  
A. Morlet ◽  
N.S. Moise ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Intracardiac Echocardiography ◽  
Device Closure ◽  
Transcatheter Device ◽  
Patent Ductus

scholarly journals Intravascular Hemolysis after Transcatheter Closure of a Huge Tubular Patent Ductus Arteriosus Using Cera-duct Occluder: Managed Successfully by Conservative Treatment

2021 ◽  
Vol 16 (2) ◽  
pp. 90-92
Author(s):  
Md Ferdousur Rahman Sarker ◽  
Nurun Nahar Fatema Begum ◽  
Jannatul Ferdous ◽  
Nazmul Islam Bhuiyan ◽  
Md Ashfaque Ahemmed Khan ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Transcatheter Closure ◽  
Ductus Arteriosus ◽  
Growth Failure ◽  
Female Child ◽  
Intravascular Hemolysis ◽  
Device Closure ◽  
History Of ◽  
Transcatheter Device ◽  
Patent Ductus

Isolated patent ductus arteriosus (PDA) is seen in approximately 1 in 2000 full-term life birth neonate. Transcatheter device closure is widely considered as the treatment of choice for the patient diagnosed with PDA considering the safety, efficacy and less invasiveness. Residual flow following transcatheter device closure of PDA can result in haemolysis. Our patient was a case of 9.5 years old female child weighing13 kg diagnosed as a case of large tubular PDA with severe pulmonary hypertension by echocardiography. The patient had history of recurrent chest infection, breathlessness on exertion, and growth failure. The PDA was closed by transcatheter approach using Cera-duct occluder. The patient subsequently developed hemolysis which started 18 hrs after the intervention and the resolution of hemolysis achieved by conservative management within 72 hours. JAFMC Bangladesh. Vol 16, No 2 (December) 2020: 90-92  

scholarly journals Safety and efficacy of transcatheter device closure of patent ductus arteriosus in pediatric patients: Long-term outcomes

Heart India ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 80
Author(s):  
JayalHasmukhbhai Shah ◽  
DharminKhimjibhai Bhalodiya ◽  
AbhishekRawal Pravinchandra ◽  
SanketP Saraiya
Keyword(s):  
Patent Ductus Arteriosus ◽  
Pediatric Patients ◽  
Ductus Arteriosus ◽  
Device Closure ◽  
Long Term Outcomes ◽  
Safety And Efficacy ◽  
Transcatheter Device ◽  
Patent Ductus

Intravascular ultrasonography-guided measurement and transcatheter closure of highly calcified patent ductus arteriosus in an older adult

2021 ◽  
pp. 1-3
Author(s):  
Yoko Kawai ◽  
Takeshi Nakamura ◽  
Satoaki Matoba
Keyword(s):  
Older Adults ◽  
Patent Ductus Arteriosus ◽  
Older Adult ◽  
Transcatheter Closure ◽  
Ductus Arteriosus ◽  
Ct Images ◽  
Device Closure ◽  
Intravascular Ultrasonography ◽  
Patent Ductus

Abstract In older adults with patent ductus arteriosus, CT is widely used for duct visualisation because angiography images can be inadequate for evaluation. We report the case of a 73-year-old woman with a highly calcified patent ductus arteriosus whose CT images were insufficient for accurate measurement. Intravascular ultrasonography is useful for sizing of and guiding device closure of the duct.

scholarly journals Device closure of patent ductus arteriosus: analysis of cases in a Bangladeshi centre

2020 ◽  
Vol 7 (7) ◽  
pp. 1481
Author(s):  
Nurun N. Fatema ◽  
Abul K. M. Razzaque
Keyword(s):  
Patent Ductus Arteriosus ◽  
Transcatheter Closure ◽  
Ductus Arteriosus ◽  
Age Groups ◽  
Device Closure ◽  
Catheterization Laboratory ◽  
Congenital Rubella ◽  
First Choice ◽  
Associated Conditions ◽  
Patent Ductus

Background: Transcatheter closure of Patent ductus arteriosus (PDA) has become the first-choice therapy for closure in patients of any age group. Authors reviewed the outcome of device closure in all age groups starting from neonate to adult.Methods: From December 2014 to December 2019, 440 cases underwent transcatheter closure in a catheterization laboratory of a tertiary level cardiac hospital. Selection criteria were isolated PDA or PDA with associated conditions which can be managed in the same setting by an intervention. Exclusion criteria were proven Eisenmenger syndrome. A retrospective review of outcome and complications were recorded from computerized data records.Results: Age of the patient varied from 10 days to 65 years. The median age was 3 years. Most of the patients were female (63%), weight varied from 1.8 kg to 75 kg. the median weight was 7.5 kg. Isolated PDA cases were 74.77 %. Among syndromes, congenital rubella syndrome was common (7.5%), followed by Down Syndrome (6.36%). The narrowest PDA diameter varied for 1.8 mm - 14 mm with a median of 5 mm. Among duct occluders, 8x6 mm CeraTM was the commonest one used in the study population. Complete occlusion was observed in 99.55% of cases.Conclusions: Transcatheter closure of PDA is considered safe and efficacious in all age groups. It is the gold standard now and replaced surgical option in most of the places.

scholarly journals MANAGEMENT OF HYPERTENSIVE PDA

2021 ◽  
Vol 70 (Suppl-4) ◽  
pp. S701-05
Author(s):  
Khushal Khan Khattak ◽  
Maad Ullah ◽  
Abdul Malik Sheikh ◽  
Asma Kanwal ◽  
Sajid Ali Shah ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Artery ◽  
Patent Ductus Arteriosus ◽  
Palliative Treatment ◽  
Ductus Arteriosus ◽  
Treatment Options ◽  
Device Closure ◽  
Surgical Ligation ◽  
Percutaneous Catheter ◽  
Patent Ductus

Objective: To determine different treatment options in patients of Patent Ductus Arteriosus with pulmonary hypertension beyond neonatal period. Study Design: Descriptive cross sectional study. Place and Duration of Study: This study was carried out in Pediatric Cardiology department of Rawalpindi Institute of Cardiology, from Jan 2017 to Jan 2019. Methodology: Patients having PDA with pulmonary hypertension were included in the study. Treatment options were divided into percutaneous catheter device closure, surgical ligation of patent ductus arteriosus and palliative treatment. Any adverse event during the procedure was documented. Stratification was done in regard to gender and age group. Post stratification chi square test was applied and p-value less than or equal to 0.05 was considered as significant. Results: Total number of patients included in the study were 37. Mean age (years) of patients (Mean ± SD) was 19.21 ± 8.76. Mean ± SD pulmonary artery pressure was 56.43 ± 11.55 mmHg. Percutaneous catheter device closure was successful in 24 (64.9%) patients, in 7 (18.9%) patients primary surgical PDA ligation was done, 3 (8.1%) patients were advised palliative treatment and in 3 (8.1%) patients adverse events occurred during percutaneous device closure and were thus referred for surgical ligation. Patent ductus Arteriosus Occlutech device was used in 18 (48.6%) patients, Occlutech VSD device was used in 7 (18.5%) patients and in 1 (2.7%) patient AGA duct occluder was used. Conclusion: In patients with patent ductus arteriosus and pulmonary artery hypertension, percutaneous catheter device closure is a safe and effective procedure.

Transcatheter Patent Ductus Arteriosus (PDA) Device Closure

2021 ◽  
pp. 395-403
Author(s):  
Ata Firouzi ◽  
Zahra Hosseini
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Device Closure ◽  
Patent Ductus
Sign in / Sign up

Export Citation Format

Share Document